PL2532681T3 - Przeciwciało anty-ILT7 - Google Patents

Przeciwciało anty-ILT7

Info

Publication number
PL2532681T3
PL2532681T3 PL12168586T PL12168586T PL2532681T3 PL 2532681 T3 PL2532681 T3 PL 2532681T3 PL 12168586 T PL12168586 T PL 12168586T PL 12168586 T PL12168586 T PL 12168586T PL 2532681 T3 PL2532681 T3 PL 2532681T3
Authority
PL
Poland
Prior art keywords
ilt7 antibody
ilt7
antibody
Prior art date
Application number
PL12168586T
Other languages
English (en)
Inventor
Yumiko Kamogawa
Minkwon Cho
Naoko Arai
Koji Ishida
Original Assignee
Sbi Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sbi Biotech Co Ltd filed Critical Sbi Biotech Co Ltd
Publication of PL2532681T3 publication Critical patent/PL2532681T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
PL12168586T 2005-12-20 2006-12-20 Przeciwciało anty-ILT7 PL2532681T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005366465 2005-12-20
EP12168586.1A EP2532681B1 (en) 2005-12-20 2006-12-20 Anti-ILT7 antibody
EP06842945.5A EP1964852B1 (en) 2005-12-20 2006-12-20 Anti-ilt7 antibody

Publications (1)

Publication Number Publication Date
PL2532681T3 true PL2532681T3 (pl) 2015-03-31

Family

ID=38188642

Family Applications (3)

Application Number Title Priority Date Filing Date
PL06842945T PL1964852T3 (pl) 2005-12-20 2006-12-20 Przeciwciało anty-ilt7
PL12168586T PL2532681T3 (pl) 2005-12-20 2006-12-20 Przeciwciało anty-ILT7
PL14186905T PL2913343T3 (pl) 2005-12-20 2006-12-20 Przeciwciało przeciw ilt7

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL06842945T PL1964852T3 (pl) 2005-12-20 2006-12-20 Przeciwciało anty-ilt7

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14186905T PL2913343T3 (pl) 2005-12-20 2006-12-20 Przeciwciało przeciw ilt7

Country Status (29)

Country Link
US (6) US8084585B2 (pl)
EP (4) EP1964852B1 (pl)
JP (2) JP5020828B2 (pl)
KR (3) KR101585532B1 (pl)
CN (5) CN105111311B (pl)
AU (1) AU2006328470B2 (pl)
BR (1) BRPI0620141B1 (pl)
CA (2) CA2634116C (pl)
CY (3) CY1114227T1 (pl)
DK (3) DK2532681T3 (pl)
ES (3) ES2526079T3 (pl)
HK (1) HK1218126A1 (pl)
HR (2) HRP20130494T1 (pl)
HU (1) HUE039865T2 (pl)
IL (1) IL192266A (pl)
LT (1) LT2913343T (pl)
ME (1) ME02111B (pl)
MX (1) MX2008007682A (pl)
NZ (3) NZ569910A (pl)
PL (3) PL1964852T3 (pl)
PT (3) PT2532681E (pl)
RS (2) RS52860B (pl)
RU (2) RU2456298C2 (pl)
SG (2) SG170749A1 (pl)
SI (3) SI2913343T1 (pl)
TR (1) TR201816574T4 (pl)
UA (1) UA97946C2 (pl)
WO (1) WO2007072866A1 (pl)
ZA (1) ZA200805850B (pl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
AU2010319531A1 (en) * 2009-11-10 2012-05-24 Amgen Inc. Anti-c-MPL antibodies
WO2011063237A2 (en) * 2009-11-19 2011-05-26 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof
KR20230044026A (ko) 2010-02-24 2023-03-31 이뮤노젠 아이엔씨 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
EP3085387A1 (en) * 2010-04-26 2016-10-26 Abraxis BioScience, LLC Sparc binding antibodies and uses thereof
EA201791843A3 (ru) 2011-04-01 2018-05-31 Иммьюноджен, Инк. Способы повышения эффективности folr1 терапии рака
DK2828284T3 (da) 2012-03-20 2019-06-11 Biogen Ma Inc Jcv-neutraliserende antistoffer
WO2013142300A2 (en) * 2012-03-20 2013-09-26 Biogen Idec Ma Inc. Jcv neutralizing antibodies
JP6403166B2 (ja) 2012-08-03 2018-10-10 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 単一抗原抗ｐｄ−ｌ１およびｐｄ−ｌ２二重結合抗体およびその使用方法
EP2890717B1 (en) 2012-08-31 2020-03-04 ImmunoGen, Inc. Diagnostic assays and kits for detection of folate receptor 1
IL244061B (en) 2013-08-30 2022-07-01 Immunogen Inc Antibodies and assays for the detection of folate receptor 1
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
CN105829534B (zh) * 2013-12-24 2021-08-03 安斯泰来制药株式会社 抗人bdca-2抗体
ES2941897T3 (es) 2014-11-12 2023-05-26 Seagen Inc Compuestos que interaccionan con glicanos y procedimientos de uso
SG11201706786UA (en) * 2015-03-18 2017-09-28 Seattle Genetics Inc Cd48 antibodies and conjugates thereof
SG10202005144TA (en) * 2015-06-29 2020-07-29 Immunogen Inc Anti-cd123 antibodies and conjugates and derivatives thereof
AU2016323968B2 (en) 2015-09-17 2023-07-06 Immunogen, Inc. Therapeutic combinations comprising anti-FOLR1 immunoconjugates
SG11201803213XA (en) 2015-11-12 2018-05-30 Siamab Therapeutics Inc Glycan-interacting compounds and methods of use
AU2016355206A1 (en) * 2015-11-19 2018-05-24 Abbvie Stemcentrx Llc Novel anti-EMR2 antibodies and methods of use
WO2017130060A1 (en) 2016-01-26 2017-08-03 Ciriello Christopher John Automated dental treatment system
WO2017132486A1 (en) * 2016-01-27 2017-08-03 Siamab Therapeutics, Inc. Compositions and methods for targeting cancer stem cells
IL296874A (en) * 2016-03-01 2022-11-01 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Antibodies specific for the human poliovirus receptor
US11072652B2 (en) * 2016-03-10 2021-07-27 Viela Bio, Inc. ILT7 binding molecules and methods of using the same
CN116790614A (zh) 2016-04-04 2023-09-22 比奥贝拉蒂美国公司 抗补体因子bb抗体以及其用途
KR20240044544A (ko) 2017-03-03 2024-04-04 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
KR20200042937A (ko) 2017-08-30 2020-04-24 페인스 테라퓨틱스 인코포레이티드 항-lag-3 항체 및 이의 용도
WO2019075220A1 (en) 2017-10-11 2019-04-18 Bioverativ Usa Inc. METHODS FOR INDUCING COMPLEMENT ACTIVITY
AU2018367524B2 (en) * 2017-11-17 2022-09-15 Merck Sharp & Dohme Llc Antibodies specific for immunoglobulin-like transcript 3 (ILT3) and uses thereof
US11396538B2 (en) 2017-12-20 2022-07-26 Radimmune Therapeutics, Inc. Antibodies to centrin-1, methods of making, and uses thereof
US11655295B2 (en) * 2018-01-18 2023-05-23 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-LAG-3 antibody and use thereof
TW202003576A (zh) * 2018-05-10 2020-01-16 美商艾博視訊有限公司 活化cd40之單株抗體及其用途
KR20210021969A (ko) 2018-05-10 2021-03-02 사이버돈틱스 (유에스에이), 인크. 자동화된 치과 드릴
PH12022550333A1 (en) * 2019-08-12 2023-06-14 Biond Biologics Ltd Antibodies against ilt2 and use thereof
JP7754506B2 (ja) 2019-10-08 2025-10-15 ネクチン セラピューティクス エルティーディー． ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用
JP2023505203A (ja) * 2019-12-06 2023-02-08 ビエラ バイオ インコーポレイテッド Ｉｌｔ７結合タンパク質を使用した治療方法
PH12022552558A1 (en) 2020-04-20 2024-04-22 Genzyme Corp Humanized anti-complement factor bb antibodies and uses thereof
WO2022051516A1 (en) 2020-09-03 2022-03-10 Cyberdontics (Usa), Inc. Method and apparatus for cna analysis of tooth anatomy
MX2023013015A (es) 2021-05-04 2023-11-15 Viela Bio Inc Metodos de tratamiento de trastornos autoinmunitarios con proteinas de union al transcrito 7 similar a inmunoglobulina (ilt7).
CA3261409A1 (en) 2022-07-27 2024-02-01 Viela Bio, Inc. FORMULATIONS CONTAINING AN IMMUNOGLOBULIN 7-TYPE TRANSCRIPT-BINDING PROTEIN (ILT7)
CN115819604B (zh) * 2022-09-09 2025-04-15 季华实验室 抗双链dna抗体、核苷酸片段、磁珠及提取外周血游离dna的方法
EP4680344A1 (en) * 2023-03-16 2026-01-21 Inmagene Pte. Ltd. Ilt7-targeting antibodies and uses thereof
CN116948032B (zh) * 2023-09-19 2023-12-12 汇智生物技术(苏州)有限公司 人源cd4单克隆抗体及其制备方法和应用
CN120098124A (zh) * 2023-12-05 2025-06-06 苏州普乐康医药科技有限公司 一种抗bdca-2抗体及其制备方法和应用
WO2026002175A1 (zh) * 2024-06-27 2026-01-02 无锡徕特康生物科技有限公司 靶向ilt7和cd89的髓细胞衔接子抗体及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA952797B (en) * 1994-04-12 1996-10-07 Res Dev Foundation Method of treating auto-immune diseases using type one interferons
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
DK1156823T3 (da) * 1999-02-12 2009-01-19 Scripps Research Inst Fremgangsmåder til behandling af tumorer og metastaser ved anvendelse af en kombination af anti-angiogene terapier og immunoterapier
KR100951067B1 (ko) * 2000-02-10 2010-04-07 아보트 러보러터리즈 사람 인터류킨-18에 결합하는 항체 및 이를 제조하고사용하는 방법
US6897067B2 (en) * 2000-11-03 2005-05-24 Regents Of The University Of Michigan Surface transfection and expression procedure
US20040241167A1 (en) * 2001-06-25 2004-12-02 Nicole Suciu-Foca Ilt3 and ilt4-related compositons and methods
WO2003012061A2 (en) 2001-08-01 2003-02-13 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
CN1568330A (zh) * 2001-10-13 2005-01-19 埃斯特瑞恩有限公司 含有糖基化磷脂酰肌醇的嵌合多肽
PL210412B1 (pl) * 2002-05-24 2012-01-31 Schering Corp Izolowane przeciwciało anty-IGFR lub jego fragment, kompozycja farmaceutyczna, zastosowanie, kwas nukleinowy, zrekombinowany wektor, komórka gospodarza, kompleks, polipeptyd i sposób jego wytwarzania
JP4498136B2 (ja) 2002-08-01 2010-07-07 Ｓｂｉバイオテック株式会社 マウスインターフェロン産生細胞の検出方法
WO2004023973A2 (en) * 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics
EP1664762A4 (en) 2003-09-03 2008-08-13 Us Gov Health & Human Serv METHOD OF IDENTIFYING AND DIAGNOSIS OF, AND VIEWING, SURVIVAL IN LYMPHOMA
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound

Also Published As

Publication number Publication date
CY1121294T1 (el) 2020-05-29
CN105111311A (zh) 2015-12-02
US20160130343A1 (en) 2016-05-12
PT2913343T (pt) 2018-11-21
DK2532681T3 (en) 2015-01-05
WO2007072866A1 (ja) 2007-06-28
CN105111311B (zh) 2019-10-18
CN110776566A (zh) 2020-02-11
CN120718150A (zh) 2025-09-30
US20200339682A1 (en) 2020-10-29
CN103360492A (zh) 2013-10-23
JP5020828B2 (ja) 2012-09-05
JPWO2007072866A1 (ja) 2009-06-04
RU2012112046A (ru) 2013-10-10
KR101624587B1 (ko) 2016-05-26
CA2994756C (en) 2020-10-27
EP1964852B1 (en) 2013-04-17
PT2532681E (pt) 2014-12-23
BRPI0620141A2 (pt) 2011-11-01
SI2913343T1 (sl) 2019-01-31
NZ569910A (en) 2012-06-29
HK1214603A1 (en) 2016-07-29
PL2913343T3 (pl) 2019-03-29
EP2532681B1 (en) 2014-10-01
ES2416716T3 (es) 2013-08-02
IL192266A0 (en) 2008-12-29
CA2634116A1 (en) 2007-06-28
TR201816574T4 (tr) 2018-11-21
DK2913343T3 (en) 2018-11-26
US8470992B2 (en) 2013-06-25
CN101379089A (zh) 2009-03-04
NZ599683A (en) 2013-11-29
ES2699428T3 (es) 2019-02-11
RS52860B (sr) 2013-12-31
HK1218126A1 (zh) 2017-02-03
ME02111B (me) 2015-10-20
EP2913343B1 (en) 2018-08-08
CY1114227T1 (el) 2016-08-31
KR20140053232A (ko) 2014-05-07
JP5420688B2 (ja) 2014-02-19
US20090280128A1 (en) 2009-11-12
EP1964852A1 (en) 2008-09-03
SG170749A1 (en) 2011-05-30
PT1964852E (pt) 2013-07-10
DK1964852T3 (da) 2013-07-08
KR20080090430A (ko) 2008-10-08
RU2599450C2 (ru) 2016-10-10
BRPI0620141B1 (pt) 2024-04-30
US8084585B2 (en) 2011-12-27
SG10201602095PA (en) 2016-05-30
SI1964852T1 (sl) 2013-09-30
CA2994756A1 (en) 2007-06-28
CN101379089B (zh) 2013-08-07
UA97946C2 (ru) 2012-04-10
KR101585532B1 (ko) 2016-01-14
AU2006328470A1 (en) 2007-06-28
HK1124347A1 (en) 2009-07-10
AU2006328470B2 (en) 2012-08-16
RU2456298C2 (ru) 2012-07-20
EP2532681A1 (en) 2012-12-12
RU2008129715A (ru) 2010-01-27
KR101526934B1 (ko) 2015-06-26
US20120135003A1 (en) 2012-05-31
HUE039865T2 (hu) 2019-02-28
ES2526079T3 (es) 2015-01-05
MX2008007682A (es) 2008-10-23
ZA200805850B (en) 2009-04-29
CN110776566B (zh) 2025-07-15
HK1179638A1 (en) 2013-10-04
EP2913343A1 (en) 2015-09-02
HRP20141226T1 (hr) 2015-02-27
SI2532681T1 (sl) 2015-03-31
AU2006328470A2 (en) 2008-10-09
EP1964852A4 (en) 2010-02-24
JP2012143232A (ja) 2012-08-02
CY1116031T1 (el) 2017-01-25
EP3441403A1 (en) 2019-02-13
US20170204179A1 (en) 2017-07-20
LT2913343T (lt) 2018-11-26
PL1964852T3 (pl) 2013-09-30
NZ616992A (en) 2015-07-31
CA2634116C (en) 2018-03-27
IL192266A (en) 2014-09-30
KR20150031485A (ko) 2015-03-24
US20130259872A1 (en) 2013-10-03
HRP20130494T1 (en) 2013-08-31
RS53752B1 (sr) 2015-06-30

Similar Documents

Publication Publication Date Title
IL187106A (en) Sclerostin binds antibody
IL190472A0 (en) Anti-glypican-3 antibody
ZA200805850B (en) Anti-ILT7 antibody
IL185366A0 (en) Antibody
SG10201404801YA (en) Monoclonal antibody
IL181575A0 (en) Anti-ox40l antibodies
IL185380A0 (en) ANTI-MAdCAM ANTIBODY COMPOSITIONS
IL228033A0 (en) Antibodies
PL2011869T3 (pl) Nowe przeciwciało anty-CD98
ZA200709456B (en) Anti-IL2 antibodies
GB0615662D0 (en) Antibody
GB0420466D0 (en) Anti-glucan antibodies
GB0517487D0 (en) Antibodies
ZA200701952B (en) Anti-OX40L antibodies
GB0624980D0 (en) Modification
IL215528A0 (en) Improved immunoassay methods
EP1896047A4 (en) ANTI-GFRALPHA3 ANTIBODIES
EP1780221A4 (en) ANTI-SYNOVIOLIN ANTIBODY
GB0505489D0 (en) Antibodies
GB0418415D0 (en) Antibody
GB0512278D0 (en) Antibodies
GB0505054D0 (en) Antibodies
GB0500400D0 (en) Antibody
GB0420771D0 (en) Antibody
GB0519883D0 (en) Antibodies